Decoding neurons to unlock breakthrough cns therapeutics
Mission
To accelerate discovery of empirically grounded, AI-driven therapeutics that deliver transformative value to patients with neurological disease - all powered through Quiver's innovation engine and strategic partnerships.
The opportunity
Brain health is a growing global crisis, but neurological drug development continues to see the lowest success rates. Most failures trace back to weak targets, unexpected toxicities, and misaligned patient selection—issues driven by the historical lack of scalable human-relevant models, reliable neural measurements, and the computational power needed to decode complex brain biology.
Quiver's Solution
Our value proposition is simple: safer, more effective CNS drugs, discovered faster and at lower cost, with human relevance built in from day one. Our approach integrates cutting-edge scalable biology, state-of-the-art technology and engineering, and learning and surrogate models to identify novel therapeutic targets and the best candidate molecules to deliver new and meaningful therapeutics to patients.
Quiver's Solution
Our value proposition is simple: safer, more effective CNS drugs, discovered faster and at lower cost, with human relevance built in from day one. Our approach integrates cutting-edge scalable biology, state-of-the-art technology and engineering, and learning and surrogate models to identify novel therapeutic targets and the best candidate molecules to deliver new and meaningful therapeutics to patients.
OUR PLATFORM-POWERED THERAPEUTIC PIPELINE
best molecule (Efficacy/Toxicity)
and the best molecule
+Additional early discovery programs not listed include: SCN8A ASO, Dual Nav1.7/1.8 ASO, Nav1.8 SM, ‡Signed in Q4 2025
